RBC Life Sciences (RBCL) 10-Q 2012 Q2 Quarterly report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2012

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________________ to ________________

Commission file number:  000-50417

RBC Life Sciences, Inc.

(Exact name of registrant as specified in its charter)

Nevada	91-2015186
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)
2301 Crown Court, Irving, Texas	75038
(Address of principal executive offices)	(Zip Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes x     No  o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).     Yes x     No  o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	o		Accelerated filer	o
Non-accelerated filer	o	(Do not check if a smaller reporting company)	Smaller reporting company	x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)     Yes o     No  x

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class	Outstanding at July 27, 2012
Common Stock, $0.001 par value per share	22,228,834 shares

TABLE OF CONTENTS

		Page Number
PART I – FINANCIAL INFORMATION
Item 1.	Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	19
Item 4.	Controls and Procedures	20
PART II – OTHER INFORMATION
Item 1.	Legal Proceedings	21
Item 1A.	Risk Factors	21
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21
Item 3.	Defaults Upon Senior Securities	21
Item 4.	Reserved	21
Item 5.	Other Information	21
Item 6.	Exhibits	21
Signatures		22
Exhibit Index		23

PART 1 – FINANCIAL INFORMATION

ITEM 1.             FINANCIAL STATEMENTS

RBC LIFE SCIENCES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30, 2012			December 31, 2011
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	3,163,611		$	3,858,544
Accounts receivable, net of allowance for doubtful accounts of $30,137 and $29,361, respectively	961,579			585,593
Inventories	6,441,850			6,448,934
Deferred income taxes	455,493			460,868
Prepaid expenses and other current assets	937,304			623,288
Total current assets	11,959,837			11,977,227
Property and equipment, net	4,280,724			4,486,771
Goodwill, net	2,285,727			2,286,859
Intangible assets, net	46,915			49,894
Other assets	29,718			24,995
	$	18,602,921		$	18,825,746
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable, trade	$	2,141,077		$	2,170,690
Accrued liabilities	1,061,498			1,065,840
Current maturities of long-term obligations	189,226			182,056
Deferred revenue	2,968,658			2,990,333
Total current liabilities	6,360,459			6,408,919
Long-term obligations, less current maturities	1,449,059			1,545,499
Deferred income taxes	969,109			1,007,977
Shareholders’ equity:
Common stock, $0.001 par value; 50,000,000 shares authorized; 22,228,834 shares issued and outstanding at June 30, 2012 and December 31, 2011	22,229			22,229
Additional paid-in capital	13,668,137			13,650,414
Accumulated deficit	(4,002,660		)	(3,952,842		)
Accumulated other comprehensive income	136,588			143,550
	9,824,294			9,863,351
	$	18,602,921		$	18,825,746

See notes to condensed consolidated financial statements.

- 3 -

RBC LIFE SCIENCES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

	Quarters Ended June 30,				Six Months Ended June 30,
	2012		2011		2012			2011
Net sales	$	6,548,991	$	7,494,068	$	12,617,370		$	14,031,951
Cost of sales	3,093,862		3,509,250		6,033,457			6,730,968
Gross profit	3,455,129		3,984,818		6,583,913			7,300,983
Operating expenses:
General and administrative	2,369,886		2,330,339		4,689,831			4,440,354
Distributor commissions	886,005		1,488,918		1,659,163			2,323,482
Depreciation and amortization	123,463		108,225		246,180			218,268
Total operating expenses	3,379,354		3,927,482		6,595,174			6,982,104
Operating profit (loss)	75,775		57,336		(11,261		)	318,879
Interest expense	32,034		35,406		64,936			71,615
Earnings (loss) before income taxes	43,741		21,930		(76,197		)	247,264
Provision (benefit) for income taxes	20,621		4,900		(26,379		)	86,900
Net earnings (loss)	23,120		17,030		(49,818		)	160,364
Other comprehensive income (loss):
Foreign currency translation adjustment	7,029		343		(6,962		)	(2,869		)
Comprehensive income (loss)	$	30,149	$	17,373	$	(56,780	)	$	157,495

Net earnings (loss) per share:
Basic	$	0.00	$	0.00	$	(0.00	)	$	0.01
Diluted	$	0.00	$	0.00	$	(0.00	)	$	0.01

Weighted average common shares outstanding:
Basic	22,228,834	22,228,834	22,228,834	22,228,834
Diluted	22,272,490	22,548,108	22,228,834	22,547,168

See notes to condensed consolidated financial statements.

- 4 -

RBC LIFE SCIENCES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Six Months Ended June 30,
	2012			2011
Cash flows from operating activities:
Net earnings (loss)	$	(49,818	)	$	160,364
Adjustment for non-cash items:
Depreciation and amortization	279,355			253,143
Stock-based compensation	17,723			21,615
Deferred income taxes	(33,616		)	(11,414		)
Change in operating assets and liabilities:
Accounts receivable	(375,969		)	(72,961		)
Inventories	10,628			(202,699		)
Prepaid expenses and other current assets	(314,161		)	(369,832		)
Other assets	(4,399		)	(20,984		)
Accounts payable and accrued liabilities	(34,572		)	720,473
Deferred revenue	(21,541		)	1,083,327
Net cash provided by (used in) operating activities	(526,370		)	1,561,032
Cash flows from investing activities:
Purchase of property and equipment	(69,928		)	(65,274		)
Net cash used in investing activities	(69,928		)	(65,274		)
Cash flows from financing activities:
Payments of long-term obligations	(89,270		)	(82,634		)
Net cash used in financing activities	(89,270		)	(82,634		)
Effect of exchange rate changes on cash flows	(9,365		)	(19,055		)
Net increase (decrease) in cash and cash equivalents	(694,933		)	1,394,069
Cash and cash equivalents, beginning of period	3,858,544			4,220,152
Cash and cash equivalents, end of period	$	3,163,611		$	5,614,221

See notes to condensed consolidated financial statements.

- 5 -

RBC LIFE SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note A – Unaudited Condensed Consolidated Financial Statements:

The accompanying unaudited condensed consolidated financial statements of RBC Life Sciences, Inc. (sometimes hereinafter referred to collectively as “we”, “our”, “RBC” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the U.S. (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Certain information and disclosures that are normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to these rules and regulations.  These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2011 (the “2011 Form 10-K”), previously filed with the Securities and Exchange Commission.

In the opinion of management, all adjustments (consisting solely of normal recurring accruals) considered necessary for a fair presentation of the Company's results for the interim periods have been included.  The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates.  The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for the full year.  Subsequent events were evaluated through the issuance date of the condensed consolidated financial statements.

New Accounting Pronouncement

In June 2011, the FASB issued ASU No. 2011-05, Comprehensive Income (Topic 220) - Presentation of Comprehensive Income ("ASU 2011-05"). ASU 2011-05 requires an entity to present components of net income and other comprehensive income either in one continuous statement of comprehensive income or in two separate but consecutive statements. ASU 2011-05 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011 and must be applied retrospectively. The Company adopted the provisions of ASU 2011-05 as of January 1, 2012 using the single continuous statement presentation. The adoption of this guidance did not have a material effect on the Company's consolidated financial statements.

Note B – Nature of Operations and Organization:

The Company is principally engaged in the marketing of nutritional supplements and personal care products (collectively “Nutritional Products”) through subsidiaries in the U.S. and Canada and branch operations in Taiwan.  This product line is marketed under the “RBC Life” brand name.  In certain markets, primarily the U.S., Canada and Taiwan, the Company markets its products through a network of distributors that are referred to as “Associates.”  The Associates are independent contractors who purchase products for personal use, purchase products for resale to retail customers and sponsor other individuals as Associates.  Accordingly, Associates may be product consumers only or they may also seek to derive compensation both from the direct sales of products and from sales generated by sponsored Associates. In certain markets in Southeast Asia, the Company sells its products through a not-for-resale ("NFR") program. Individuals who participate in the NFR program function similarly to other Associates in that they can sponsor others and derive compensation from sales generated by individuals they sponsor. However, they may only order products for personal use and may not resell products to retail customers.

RBC also markets its Nutritional Products in certain international markets through license arrangements.  The licensees are third parties who are granted exclusive rights to distribute RBC products in their respective territories and, for the most part, distribute these products through an independent Associate network in the licensed territory.  Under these arrangements, the independent Associate network in a licensed territory is compensated by the licensee in accordance with a compensation plan similar to the one used by RBC for its Associates.

In addition to its Nutritional Products, RBC also markets a line of wound care products (“Medical Products”) under the MPM Medical brand name through a U.S. subsidiary.  Medical Products are distributed primarily in the U.S. to hospitals, nursing homes, clinics and pharmacies through traditional medical/surgical supply dealers and pharmaceutical distributors.  Medical Products are used to prevent and treat wounds, and manage pain associated with wounds, in the acute care, long-term care and oncology markets.

- 6 -

Note C – Inventories:

Inventories consist of the following:

	June 30, 2012		December 31, 2011
Raw materials and bulk products	$	341,590	$	373,409
Packaging materials	362,641		346,844
Finished goods	5,737,619		5,728,681
	$	6,441,850	$	6,448,934

Note D – Prepaid Expenses and Other Current Assets:

Prepaid expenses and other current assets consist of the following:

	June 30, 2012		December 31, 2011
Advance payment to suppliers	$	362,718	$	290,373
Prepaid income taxes	—		76,557
Certificates of deposit - restricted	83,419		83,598
Prepaid insurance and other	491,167		172,760
	$	937,304	$	623,288

At June 30, 2012 and December 31, 2011, the Company held certificates of deposit in the amounts of approximately $83,000 and $84,000, respectively, which were pledged to secure surety bonds.

Note E – Property and Equipment:

Property and equipment consists of the following:

	June 30, 2012			December 31, 2011
Building and improvements	$	3,523,428		$	3,523,428
Computer software and office equipment	2,451,723			2,381,345
Warehouse equipment	235,632			235,632
Automotive equipment	14,717			14,717
	6,225,500			6,155,122
Less – accumulated depreciation	(3,085,949		)	(2,809,524		)
	3,139,551			3,345,598
Land	1,141,173			1,141,173
	$	4,280,724		$	4,486,771

Depreciation expense totaled approximately $138,500 and $124,300 for the quarters ended June 30, 2012 and 2011, respectively, and $276,400 and $250,100 for the six months ended June 30, 2012 and 2011, respectively.

Note F – Goodwill and Other Intangible Assets:

The Company measures its goodwill for impairment at the end of each year or in the event of an impairment indicator.  No impairment losses have been recognized as a result of this testing.  Goodwill balances are summarized as follows:

	Gross Carrying Value			Accumulated Amortization
Balance, December 31, 2011	$	3,413,527		$	(1,126,668	)
Currency translation adjustment	(2,210		)	1,078
Balance, June 30, 2012	$	3,411,317		$	(1,125,590	)

- 7 -

Other intangible assets consist of the following:

		June 30, 2012					December 31, 2011
	Average Life (years)	Gross Carrying Value		Accumulated Amortization			Gross Carrying Value		Accumulated Amortization
Copyrights, trademarks and other registrations	19	$	99,100	$	(57,477	)	$	99,100	$	(54,834	)
Other	19	12,600		(7,308		)	12,600		(6,972		)
		$	111,700	$	(64,785	)	$	111,700	$	(61,806	)

Amortization expense related to other intangible assets totaled approximately $1,500 for the quarters ended June 30, 2012 and 2011 and $3,000 for the six months ended June 30, 2012 and 2011.  The aggregate estimated amortization expense for intangible assets remaining as of June 30, 2012 is as follows:

Remainder of 2012	$	2,979
2013	5,957
2014	5,957
2015	5,957
2016	5,957
Thereafter	20,108
	$	46,915

Note G – Accrued Liabilities:

Accrued liabilities consist of the following:

	June 30, 2012		December 31, 2011
Distributor commissions	$	500,434	$	511,360
Salaries and wages	354,725		485,927
Sales and property taxes	60,002		31,923
Interest	10,580		11,157
Other	135,757		25,473
	$	1,061,498	$	1,065,840

Note H – Long-Term Obligations:

Long-term obligations consist of the following:

	June 30, 2012			December 31, 2011
Mortgage note payable bearing interest at 7.75%, payable in monthly installments of $25,797 through April 2019, collateralized by land and building, and personally guaranteed by the Company’s Chairman of the Board and Chief Executive Officer	$	1,638,285		$	1,727,555
Less – current maturities	(189,226		)	(182,056		)
	$	1,449,059		$	1,545,499

The fair value of long-term debt is estimated based on interest rates for the same or similar instruments offered having the same or similar maturities and collateral requirements.  At June 30, 2012, the fair value of fixed-rate long-term debt was approximately $1,824,000, which was $186,000 above the carrying value of approximately $1,638,000.  At December 31, 2011, the fair value of fixed-rate long-term debt was approximately $1,931,000, which was $203,000 above the carrying value of approximately $1,728,000.

Note I – Share-Based Compensation:

The Company records compensation expense for all share-based payments based on the estimated grant date fair value.  Share-

- 8 -

based compensation expense was approximately $8,800 and $11,200 for the quarters ended June 30, 2012 and 2011, respectively, and $17,700 and $21,600 for the six months ended June 30, 2012 and 2011, respectively.  Share-based compensation is classified as a general and administrative expense.  There were no material tax benefits related to this expense because virtually all share-based compensation resulted from grants of incentive stock options.

The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:

	Quarters Ended June 30,				Six Months Ended June 30,
	2012		2011		2012		2011
			(1)
Weighted average expected life (years)	6.0		—		6.0		8.4
Risk-free interest rate	0.96	%	—	%	0.96	%	3.32	%
Expected volatility	310.09	%	—	%	310.09	%	96.23	%
Expected dividend yield	—	%	—	%	—	%	—	%

__________________

(1) There were no option grants during this period.

A summary of stock option activity for the six months ended June 30, 2012 is as follows:

	Options		Weighted-Average Exercise Price per Share		Weighted-Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding on December 31, 2011	1,190,570		$	0.33
Granted	100,000		0.25
Exercised	—		—
Forfeited/canceled	(13,820	)	0.62
Outstanding on June 30, 2012	1,276,750		$	0.32	3.4	$	26,945
Exercisable on June 30, 2012	1,010,660		$	0.30	2.5	$	26,945

A summary of the status of the Company's non-vested stock options as of June 30, 2012 and changes during the six months then ended are presented below:

	Shares		Weighted-Average Grant Date Fair Value per Share
Non-vested stock options at December 31, 2011	179,910		$	0.44
Non-vested stock options granted	100,000		0.25
Vested stock options	—		—
Forfeited stock options	(13,820	)	0.59
Non-vested stock options at June 30, 2012	266,090		0.36

As of June 30, 2012, there was approximately $75,100 of total unrecognized compensation cost related to stock option grants.

Note J – Segments and Geographic Area:

The Company's segments are based on the organizational structure that is used by management for making operating and investment decisions and for assessing performance.  Based on this management approach, the Company has two operating segments: Nutritional Products and Medical Products.

The Nutritional Products segment manufactures and distributes a line of over 75 nutritional supplements and personal care products, including herbs, vitamins and minerals, as well as natural skin, hair and body care products.  Nutritional Products are marketed under the "RBC Life" brand name through subsidiaries in the U.S. and Canada and branch operations in Taiwan.  These products

- 9 -

are distributed by a network comprised of independent Associates and NFR program participants in certain markets, primarily the U.S., Canada and Southeast Asia, and by licensees in certain other international markets.  For the most part, licensees also market the Nutritional Products in their respective territories through a network of independent Associates.

The Medical Products segment markets a line of approximately 28 wound care products under the MPM Medical brand name through a U.S. subsidiary operating primarily in the U.S.  These wound care products are distributed to hospitals, nursing homes, home health care agencies, clinics and pharmacies through a network of medical/surgical supply dealers and pharmaceutical distributors.  Medical Products are used to prevent and treat wounds, and manage pain associated with wounds, in the acute care, long-term care and oncology markets.

The Company evaluates the performance of its segments primarily based on operating profit.  All intercompany transactions have been eliminated, and intersegment revenues are not significant.  In calculating operating profit for these two segments, administrative expenses incurred that are common to the two segments are allocated on a usage basis.

Segment information is as follows (in thousands):

	Nutritional Products			Medical Products		Consolidated
Quarter Ended June 30, 2012
Net sales	$	4,731		$	1,818	$	6,549
Depreciation and amortization	120			20		140
Operating profit (loss)	(94		)	170		76
Capital expenditures	53			—		53
Total assets	15,849			2,754		18,603
Quarter Ended June 30, 2011
Net sales	$	5,702		$	1,792	$	7,494
Depreciation and amortization	108			18		126
Operating profit	14			43		57
Capital expenditures	32			—		32
Total assets	17,457			2,793		20,250
Six Months Ended June 30, 2012
Net sales	$	9,352		$	3,265	$	12,617
Depreciation and amortization	239			40		279
Operating profit (loss)	(206		)	195		(11		)
Capital expenditures	70			—		70
Total assets	15,849			2,754		18,603
Six Months Ended June 30, 2011
Net sales	$	10,517		$	3,515	$	14,032
Depreciation and amortization	217			36		253
Operating profit	172			147		319
Capital expenditures	65			—		65
Total assets	17,457			2,793		20,250

Financial information summarized geographically is as follows (in thousands):

- 10 -

	Quarter Ended June 30, 2012				Quarter Ended June 30, 2011
	Net sales		Long-Lived assets		Net sales		Long-Lived assets
Domestic	$	2,995	$	6,006	$	3,574	$	6,351
Russia/Eastern Europe	2,649		—		2,980		—
Canada	366		533		486		555
Southeast Asia	434		104		372		26
All others	105		—		82		—
Totals	$	6,549	$	6,643	$	7,494	$	6,932
	Six Months Ended June 30, 2012				Six Months Ended June 30, 2011
	Net sales		Long-Lived assets		Net sales		Long-Lived assets
Domestic	$	5,547	$	6,006	$	6,532	$	6,351
Russia/Eastern Europe	5,385		—		6,037		—
Canada	733		533		804		555
Southeast Asia	739		104		527		26
All others	213		—		132		—
Totals	$	12,617	$	6,643	$	14,032	$	6,932

Significant Customers

The Company recorded sales of Nutritional Products to Coral Club International, Inc. ("CCI"), a licensee of the Company, in the amounts of $2,649,000 and $2,980,000 during the quarters ended June 30, 2012 and 2011, respectively, and $5,385,000 and $6,037,000 for the six months ended June 30, 2012 and 2011, respectively.  The Company also recorded sales of Medical Products to a medical/surgical dealer (see Note L for additional information related to this dealer) in the amounts of $1,110,000 and $1,078,000 during the quarters ended June 30, 2012 and 2011, respectively, and $1,900,000 and $2,148,000 for the six months ended June 30, 2012 and 2011, respectively.  In no other case did a customer of the Company account for more than 10% of net sales during the quarters ended June 30, 2012 and 2011.

- 11 -

Note K – Earnings (Loss) Per Share:

Summarized basic and diluted earnings (loss) per common share were calculated as follows:

	Net Earnings (Loss)			Weighted Average Shares	Per Share
Quarter Ended June 30, 2012
Basic earnings per common share	$	23,120		22,228,834	$	0.00
Effect of dilutive stock options	—			43,656
Diluted earnings per common share	$	23,120		22,272,490	$	0.00
Quarter Ended June 30, 2011
Basic earnings per common share	$	17,030		22,228,834	$	0.00
Effect of dilutive stock options	—			319,274
Diluted earnings per common share	$	17,030		22,548,108	$	0.00
Six Months Ended June 30, 2012
Basic loss per common share	$	(49,818	)	22,228,834	$	(0.00	)
Effect of dilutive stock options	—			—
Diluted loss per common share	$	(49,818	)	22,228,834	$	(0.00	)
Six Months Ended June 30, 2011
Basic earnings per common share	$	160,364		22,228,834	$	0.01
Effect of dilutive stock options	—			318,334
Diluted earnings per common share	$	160,364		22,547,168	$	0.01

The number of stock options that were outstanding, but not included in the computation of diluted earnings (loss) per common share because their exercise price was greater than the average market price of the common stock, or were otherwise anti-dilutive, was approximately 1,233,000 and 458,000 for the quarters ended June 30, 2012 and 2011, respectively, and 1,233,000 and 469,000 for the six months ended June 30, 2012 and 2011, respectively.

Note L – Legal Proceedings:

On February 24, 2012, a medical/surgical dealer, which accounted for $1,900,000 and $2,148,000 of the Company's sales during the six months ended June 30, 2012 and 2011, respectively, filed a voluntary petition for protection under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Central District of California in Santa Ana, California. According to its bankruptcy petition, the dealer filed its petition as the most effective means of stabilizing its finances as it seeks to resolve a reimbursement guidelines dispute with Medicare. The dealer believes that Medicare is improperly withholding payments. While the reimbursement dispute does not involve products supplied by the Company, it has negatively affected the Company's sales to this dealer. The petition states that this dealer relies on Medicare payments for more than 90% of its revenue. On March 9, 2012, the Bankruptcy Court approved a "standstill" agreement between the dealer and Medicare, which agreement provides that Medicare would pay the dealer for certain claims it was withholding and that it would process and pay certain additional claims while the parties attempted to resolve the issues underlying the dispute. In a press release issued by the dealer, the dealer indicated that this agreement would provide it with the cash it requires to continue operations in the ordinary course of business and service its customers without interruption. As of the date of the bankruptcy filing, the Company had approximately $436,000 in accounts receivable that was owed by this dealer, and it has continued to fill this dealer's post-petition purchase orders.

On May 29, 2012, the Bankruptcy Court entered an order approving a Stipulated Motion of the dealer which directed the dealer to pay the Company for products that were shipped during the twenty day period immediately preceding the petition date. The accounts receivable owed by this dealer related to these shipments was approximately $195,000. The order directed the dealer to repay the Company in six equal installments of approximately $32,500, commencing on July 1, 2012. The first of these payments was received by the Company as ordered by the bankruptcy court.

The accounts receivable balance as of July 27, 2012 was approximately $690,000. While the Company believes that the amounts due from this dealer will be collected in full, it intends to monitor these proceedings as they progress in order to appropriately assess and enforce its rights in this matter.

- 12 -

The Company is from time to time engaged in routine litigation.  The Company regularly reviews all pending litigation matters in which it is involved and establishes reserves deemed appropriate by management for these litigation matters.

- 13 -

ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto included elsewhere in this report and the audited consolidated financial statements and notes thereto included in the 2011 Form 10-K.

FORWARD-LOOKING STATEMENTS

The statements, other than statements of historical or present facts, included in this report are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the "Exchange Act").  All statements, other than statements of historical or present facts, that address activities, events, outcomes and other matters that we plan, expect, intend, assume, believe, budget, predict, forecast, project, estimate or anticipate (and other similar expressions) will, should or may occur in the future are forward-looking statements.  Forward-looking statements can be identified by the use of the words “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “objective,” “projection,” forecast,” “goal,” “believe,” and similar expressions.  These forward-looking statements are based on management's current belief, based on currently available information, as to the outcome and time of future events.  We believe that the expectations and assumptions reflected in these forward-looking statements are reasonable.  However, we cannot assure you that such expectations will occur.  Our actual future performance could differ materially from such statements.  When considering forward-looking statements, you should keep in mind the risk factors and other cautionary statements in this Form 10-Q and those previously disclosed in Item 1A to Part I of the 2011 Form 10-K.  Many of these factors are beyond the Company's ability to control or predict. We caution you not to put undue reliance on forward-looking statements or to project any future results based on such statements or on present or prior earnings levels. We do not undertake any obligation to publicly release any revisions to any forward-looking statement to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events.  Please consider our forward-looking statements in light of those risks as you read this report.

OVERVIEW

We operate in two industry segments, Nutritional Products and Medical Products.

• Through the Nutritional Products segment, we distribute products in three broad categories: wellness products, fitness products and skin care products.   Products include herbal formulas, vitamins, minerals, antioxidants and personal care products.  In certain markets, principally in the U.S., Canada and Southeast Asia, we distribute Nutritional Products directly through a network comprised of independent Associates and individuals who participate in our NFR program. In certain other markets, we distribute Nutritional Products through exclusive license arrangements with third parties who, for the most part, distribute our products through an independent Associate network in the licensed territory.

• Through the Medical Products segment, we distribute wound care products.  These products are distributed mainly in the U.S. to hospitals, nursing homes, clinics and pharmacies through traditional medical/surgical supply dealers and pharmaceutical distributors.  Medical Products are used to prevent and treat wounds, and manage pain associated with wounds, in the acute care, long-term care and oncology markets.

- 14 -

Consolidated net sales in dollars and as a percentage of consolidated net sales are as follows:

	Quarters Ended June 30,
	2012				2011
	(U.S. dollars in 000’s)
Nutritional Products:
Licensees	$	2,754	42	%	$	3,021	40	%
Associate network	1,977		30	%	2,681		36	%
	4,731		72	%	5,702		76	%
Medical Products	1,818		28	%	1,792		24	%
	$	6,549	100	%	$	7,494	100	%
	Six Months Ended June 30,
	2012				2011
	(U.S. dollars in 000’s)
Nutritional Products:
Licensees	$	5,586	44	%	$	6,110	44	%
Associate network	3,766		30	%	4,407		31	%
	9,352		74	%	10,517		75	%
Medical Products	3,265		26	%	3,515		25	%
	$	12,617	100	%	$	14,032	100	%

Licensees. Our highest revenue distribution channel is the licensee channel.  In this channel we sell Nutritional Products to third parties who purchase products from us in accordance with a license arrangement that gives the licensee exclusive rights to distribute our products in the licensed territory. For the most part, licensees are required to distribute our products in the licensed territory through network marketing. Net sales in this distribution channel are mainly dependent upon the licensee's success in building a distribution network in the licensed territory.

Our principal licensee is CCI, which accounted for 96% and 99% of licensee net sales in the six months ended June 30, 2012 and 2011, respectively. CCI distributes products in a territory comprised mainly of Russia and Eastern Europe. The President of CCI is a former member of our Board of Directors and beneficially owns approximately 18% of our outstanding common stock. Under our arrangement with CCI, CCI orders products from the Company and pays for products when they are segregated in the Company's warehouse for CCI’s account. Once segregated, products are stored until CCI provides shipping instructions; segregated products are not subject to return except in the case of a manufacturing defect.  Because we do not recognize revenue until products are shipped to CCI, the Company's sales to CCI fluctuate from quarter to quarter, based on changes in sales demand through CCI's Associate network, as well as a number of other logistical considerations. 

Net sales in this channel decreased $524,000, or 9%, during the six months ended June 30, 2012 compared with net sales for the same period in 2011 as a result of a decrease in net sales to CCI.  Net sales to CCI decreased $652,000, or 11%, for the six months ended June 30, 2012 compared to the same period in 2011.  We attribute this decline primarily to decreased in-territory demand, as well as logistical considerations affecting the timing of shipments to CCI. Reduced in-territory demand generally results in a disproportionate reduction of sales to CCI as CCI adjusts its inventory to a level commensurate with expected future sales. Backlog related to CCI’s account was $5,333,000 at June 30, 2012 compared to $7,687,000 at June 30, 2011.

Associate Network.  Sales in this channel are generally dependent upon the number and productivity of our Associates.  Accordingly, growth in sales is generally dependent upon the sponsorship of new Associates and retention of existing Associates.  Net sales through the Associate network channel decreased approximately 15% during the first six months of 2012 compared to the same period in 2011 as a result of a 26% decline in sales during the second quarter of 2012 compared to the second quarter of 2011. This decrease in second quarter sales was primarily due to certain marketing and sales initiatives conducted during the second quarter of 2011 that were not repeated in 2012. During the second quarter of 2011, we launched a new product, Stem Kine^TM, and offered special price discounts on the purchase of Stem Kine in connection with the product launch. Stem Kine is a dietary supplement that has been shown in published human clinical studies to nutritionally enable bone marrow and other stem cell-producing tissues to increase their production of stem cells, which form the natural repair and renewal system of the

- 15 -

body. In addition, we offered a high-commission entry pack program that attracted a large number of new Associates to join the Company. Existing Associates heavily promoted sales of this entry pack in the second quarter of 2011 as they sought to win a Company-sponsored sales contest that ended in June 2011 while taking advantage of the high commissions associated with this entry pack. Although these initiatives dramatically increased sales during the second quarter of 2011, they did not provide a commensurate increase in operating profits. Because of these results, these initiatives were not repeated in 2012 and, accordingly, sales in the second quarter of 2012 declined compared to sales in the second quarter of 2011.

The following table sets forth the Associate network net sales (including NFR sales) by geographic region as a percentage of total net sales for the periods indicated:

	Quarters Ended June 30,				Six Months Ended June 30,
	2012		2011		2012		2011
U.S.	60	%	68	%	61	%	70	%
Canada	18		18		19		18
Southeast Asia	22		14		20		12
	100	%	100	%	100	%	100	%

The increase in sales in Southeast Asia is attributable to the opening of branch operations in Taiwan on October 1, 2011. Although we are unable to quantify the amount, we believe that certain sales made in the U.S. in the first six months of 2011 were made to Associates with business relationships in Southeast Asia and that products initially shipped to U.S. addresses were then re-shipped by the Associates to the Southeast Asia region. We believe that this practice was much less prevalent in the first six months of 2012 with the opening of the Taiwan branch, and as Associates in NFR markets have become more familiar with our NFR program.

Medical Products. We sell Medical Products primarily in the U.S. to wholesalers such as medical/surgical dealers and pharmaceutical distributors. These wholesalers supply various health care providers such as hospitals, nursing homes, clinics and pharmacies. In some cases, wholesalers maintain their own sales forces to market products that they supply, which include our products.

This segment's largest customer, a medical/surgical dealer, accounted for 58% and 61% of Medical Products net sales during the six months ended June 30, 2012 and 2011. On February 24, 2012, this dealer filed a voluntary petition for protection under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Central District of California in Santa Ana, California. According to its bankruptcy petition, the dealer filed its petition as the most effective means of stabilizing its finances as it seeks to resolve a reimbursement guidelines dispute with Medicare. The dealer believes that Medicare is improperly withholding payments. While the reimbursement dispute does not involve products supplied by the Company, it has negatively affected the Company's sales to this dealer. The petition states that this dealer relies on Medicare payments for more than 90% of its revenue. On March 9, 2012, the Bankruptcy Court approved a "standstill" agreement between the dealer and Medicare, which provides that Medicare would pay the dealer for certain claims it was withholding and that it would process and pay certain additional claims while the parties attempted to resolve the issues underlying the dispute. In a press release issued by the dealer, the dealer indicated that this agreement would provide it with the cash it requires to continue operations in the ordinary course of business and service its customers without interruption. As of the date of the bankruptcy filing, the Company had approximately $436,000 in accounts receivable that was owed by this dealer, and it has continued to fill this dealer's post-petition purchase orders.

On May 29, 2012, the Bankruptcy Court entered an order approving a Stipulated Motion of the dealer which directed the dealer to pay the Company for products that were shipped during the 20 day period immediately preceding the petition date. The accounts receivable owed by this dealer related to these shipments was approximately $195,000. The order directed the dealer to repay the Company in six equal installments of approximately $32,500, commencing on July 1, 2012. The first of these payments was received by the Company as ordered by the bankruptcy court.

The accounts receivable balance as of July 26, 2012 was approximately $690,000. While the Company believes that the amounts due from this dealer will be collected in full, it intends to monitor these proceedings as they progress in order to appropriately assess and enforce its rights in this matter.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The preparation of our financial statements and related disclosures in conformity with US GAAP requires us to make estimates and judgments that affect the amounts reported in our financial statements and accompanying footnotes. On an on-going basis, we evaluate these estimates and assumptions based on historical experience and various other factors and circumstances. Our

- 16 -

management believes that the estimates and assumptions are reasonable in the circumstances; however, actual results may vary from these estimates and assumptions under different future circumstances.

Management believes that there have been no significant changes during the six months ended June 30, 2012 to the items that we disclosed as our critical accounting policies and estimates in Management's Discussion and Analysis of Financial Condition and Results of Operations in the 2011 Form 10-K.

RESULTS OF OPERATIONS

The following table sets forth our operating results as a percentage of net sales for the periods indicated:

	Quarters Ended June 30,				Six Months Ended June 30,
	2012		2011		2012		2011
Net sales	100.0	%	100.0	%	100.0	%	100.0	%
Cost of sales	47.2		46.8		47.8		48.0
Gross profit	52.8		53.2		52.2		52.0
Operating expenses:
General and administrative	36.2		31.1		37.2		31.6
Distributor commissions	13.5		19.9		13.1		16.6
Depreciation and amortization	1.9		1.4		2.0		1.5
Total operating expenses	51.6		52.4		52.3		49.7
Operating profit (loss)	1.2		0.8		(0.1	)	2.3
Interest expense	0.5		0.5		0.5		0.5
Earnings (loss) before income taxes	0.7		0.3		(0.6	)	1.8
Provision (benefit) for income taxes	0.3		0.1		(0.2	)	0.7
Net earnings (loss)	0.4	%	0.2	%	(0.4	)%	1.1	%

Quarter ended June 30, 2012 compared with quarter ended June 30, 2011 ($000’s except per share amounts)

Net sales. Net sales for the quarter ended June 30, 2012 were $6,549 compared with net sales for the same period in 2011 of $7,494, a decrease of $945, or 13%. This decrease resulted from a $971 decrease in net sales of Nutritional Products, partially offset by a $26 increase in net sales of Medical Products. The decrease in net sales of Nutritional Products resulted from a decrease in net sales to our Associate network of $704, and a decrease in sales to our licensees of $267.

Associate Network.  Net sales to our Associate network decreased approximately $704, or 26%, during the second quarter of 2012 primarily due to sales generated by certain marketing and sales initiatives conducted during the second quarter of 2011 that were not repeated in 2012. This sales decline is more fully described above under the section "Overview - Associate Network."

Licensees.  Net sales to our licensees decreased as a result of decreased shipments to CCI; sales to CCI decreased $331, or 11%, during the second quarter of 2012. We attribute this decline primarily to decreased in-territory sales demand, as well as logistical considerations affecting the timing of shipments to CCI. Sales to CCI can vary from quarter to quarter due to various logistical factors, sometimes significantly, irrespective of the sales demand of CCI’s Associate network.

Medical products.  The increase in net sales of Medical Products resulted from increased sales to the largest customer in this segment, which distributes wound care products and provides services to the nursing home market. Sales increased $32 during the second quarter of 2012 compared to the second quarter of 2011.  Sales to this distributor in the second quarter of 2012 were approximately $1,110, or 55% of Medical Products net sales. On February 24, 2012, this dealer filed for Chapter 11 bankruptcy protection as described above under the section "Overview - Medical Products."

Cost of sales.  Cost of sales for the quarter ended June 30, 2012 was $3,094 compared with cost of sales in the second quarter of 2011 of $3,509, a decrease of $415, or 12%. As a percentage of net sales, cost of sales was approximately 47% in the second quarter of 2012 and 2011.

General and administrative. General and administrative expenses for the quarter ended June 30, 2012 were $2,370 compared with expenses in the second quarter of 2011 of $2,330, an increase of $40, or 2%. The increase was attributable additional expenses of approximately $146 for the operation of the Taiwan branch, which opened in October 2011, and increased costs of approximately

- 17 -

$77 for product testing, which were partially offset by lower payroll and benefits expense of approximately $120 and proceeds from the licensing of a trademark of $70. As a percentage of net sales, general and administrative expenses increased to 36% in the quarter ended June 30, 2012 from 31% in the quarter ended June 30, 2011. This percentage increase is primarily due to deleveraging as a result of the sales decrease during this period.

Distributor commissions. Distributor commissions were $886 for the quarter ended June 30, 2012 compared with $1,489 in the second quarter of 2011, a decrease of $603, or 40%.  With respect to our Associate network, distributor commissions as a percentage of commissionable sales exclusive of rebates, which are recorded as a reduction of sales, decreased to approximately 44% in the second quarter of 2012 compared to 56% in the same period in 2011.  This decrease was primarily attributable to certain changes to our Associate compensation plan implemented in the first quarter of 2012, which were adopted to better balance commissions earned on sales to new Associates and sales to existing Associates. On a consolidated basis, distributor commissions as a percentage of net sales were 14% and 20% in the quarters ended June 30, 2012 and 2011, respectively.

Income taxes.  We recorded a provision for income taxes of $21 and $5 during the quarters ended June 30, 2012 and 2011, respectively, based on our estimate of the effective annual income tax rate for the applicable period.

Net earnings.  As a result of the factors described above, net earnings for the quarter ended June 30, 2012 were $23, or $0.00 per share, compared with net earnings in the second quarter of 2011 of $17, or $0.00 per share.

Six months ended June 30, 2012 compared with six months ended June 30, 2011 ($000’s except per share amounts)

Net sales. Net sales for the six months ended June 30, 2012 were $12,617 compared with net sales for the same period in 2011 of $14,032, a decrease of $1,415, or 10%. This decrease resulted from a $1,165 decrease in net sales of Nutritional Products and a $250 decrease in net sales of Medical Products. The decrease in net sales of Nutritional Products resulted from a decrease in net sales to our Associate network of $641 and a decrease in sales to our licensees of $524.

Associate Network.  Net sales to our Associate network decreased approximately $641, or 15%, during the six months ended June 30, 2012 primarily due to sales generated by certain marketing and sales initiatives conducted during the second quarter of 2011 that were not repeated in 2012. This sales decline is more fully described above under the section "Overview - Associate Network."

Licensees.  Net sales to our licensees decreased as a result of decreased shipments to CCI; sales to CCI decreased $652, or 11%, during the six months ended June 30, 2012. We attribute this decline primarily to decreased in-territory demand, as well as logistical considerations affecting the timing of shipments to CCI. Sales to CCI can vary from quarter to quarter due to various logistical factors, sometimes significantly, irrespective of the sales demand of CCI’s Associate network.

Medical products.  The decline in net sales of Medical Products resulted from decreased sales to the largest customer in this segment.   Sales to the largest customer in this segment, which distributes wound care products and provides services to the nursing home market, decreased $248 during the six months ended June 30, 2012 compared to the same period in 2011.  Sales to this distributor in the six months ended June 30, 2012 were approximately $1,900, or 58% of Medical Products net sales. On February 24, 2012, this dealer filed for Chapter 11 bankruptcy protection as described above under the section "Overview - Medical Products."

Cost of sales.  Cost of sales for the six months ended June 30, 2012 was $6,033 compared with cost of sales in the same period in 2011 of $6,731, a decrease of $698, or 10%. As a percentage of net sales, cost of sales was approximately 48% in the six months ended June 30, 2012 and 2011.

General and administrative. General and administrative expenses for the six months ended June 30, 2012 were $4,690 compared with expenses in the first six months of 2011 of $4,440, an increase of $250 or 6%. The increase was primarily attributable to additional expenses of approximately $264 for the operation of the Taiwan branch which opened in October 2011, and increased costs of approximately $228 for product testing, which were partially offset by lower payroll and benefits expense of approximately $124 and proceeds from the licensing of a trademark of $70. As a percentage of net sales, general and administrative expenses were 37% and 32% in the six months ended June 30, 2012 and 2011, respectively. This percentage increase is attributable to the increased costs associated with the operation of the Taiwan branch and product testing, as well as deleveraging as a result of the sales decrease during this period.

Distributor commissions. Distributor commissions were $1,659 for the six months ended June 30, 2012 compared with $2,323 in the first six months of 2011, a decrease of $664, or 29%.  With respect to our Associate network, distributor commissions as a percentage of commissionable sales exclusive of rebates, which are recorded as a reduction of sales, decreased to approximately 44% in the first six months of 2012 compared to 52% in the same period in 2011.  This decrease was primarily attributable to certain changes to our Associate compensation plan implemented in the first quarter of 2012, which were adopted to better balance

- 18 -

commissions earned on sales to new Associates and sales to existing Associates. On a consolidated basis, distributor commissions as a percentage of net sales were 13% and 17% in the six months ended June 30, 2012 and 2011, respectively.

Income taxes.  We recorded a benefit for income taxes of $26 during the six months ended June 30, 2012, and a provision for income taxes of $87 during the six months ended June 30, 2011, based on our estimate of the effective annual income tax rate for the applicable period.

Net earnings (loss).  As a result of the factors described above, the net loss for the six months ended June 30, 2012 was $50, or $0.00 per share, compared with net earnings in the first six months of 2011 of $160, or $0.01 per share.

LIQUIDITY AND CAPITAL RESOURCES (000’s)

Cash and working capital. During the first six months of 2012, we had a net decrease in cash of $695 compared with a net increase in cash of $1,394 in the first six months of 2011.  At June 30, 2012, we had working capital of $5,599, a $31 increase from working capital at December 31, 2011 of $5,568.   The reasons for these changes in cash and working capital are described below.

Operating activities. In the first six months of 2012, our operating activities used cash flow of $526.  In the first six months of 2011, our operating activities provided cash flow of $1,561.  The decline in operating cash flow of $2,087 was primarily due to an increase in deferred revenues in 2011 of $1,083 that did not recur in 2012, an increase in accounts payable and accrued liabilities of $720 in 2011 that did not recur in 2012, and an increase in accounts receivable in 2012 which primarily relates to the Medical Products dealer that filed for bankruptcy protection on February 24, 2012, as described above in the section "Overview - Medical Products." These were partially offset by an increase in inventory in 2011 which did not recur in 2012. In the first six months of 2012, net earnings (loss) adjusted for non-cash activities, which includes depreciation and amortization, stock-based compensation and deferred income taxes, provided cash flows of $214 compared with $424 in the first six months of 2011.

Investing activities. During the first six months of 2012, we used cash of $70 to purchase property and equipment.

Financing activities. The only financing activity during the first six months of 2012 was the repayment of long-term debt in the amount of $89.

General liquidity and cash flows. We believe that the working capital requirements of our existing operations, including the start-up of branch operations in Taiwan, can be met through available cash and cash generated from operating activities for the foreseeable future; however, an overall decrease in demand for our products could adversely affect our liquidity. In the event of a significant decrease in cash provided by our operating activities, we may seek outside sources of capital including bank borrowings or other types of debt or equity financings. We can give no assurance, however, that we would be able to obtain any additional outside financing or obtain financing on terms we would find acceptable.  We have no plans or requirements for any significant capital expenditures during the next 12 months.

Other than those factors already described, we are not aware of any trends or uncertainties that would significantly affect our liquidity or capital resources in the future.

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk.

The following discussion about our market risk includes “forward-looking statements” that involve risks and uncertainties.  Actual results could differ materially from those projected in the forward-looking statements. We do not use derivative financial instruments for speculative or trading purposes.  We are exposed to market risk from changes in foreign currency exchange rates that could affect our future results of operations and financial condition.  We manage our exposure to these risks through our regular operating and financing activities.

Foreign exchange

We conduct foreign-based operations in local currency in Canada and Taiwan that accounted for 10% of net sales during the first six months of 2012 and 6% of net sales in 2011.  Sales transactions in Southeast Asian markets other than Taiwan are denominated in U.S. dollars.

We advance funds to and from our foreign-based operations denominated in U.S. dollars, exposing our foreign operations to the

- 19 -

effect of changes in spot exchange rates of the local currency relative to the U.S. dollar.  We do not regularly use forward-exchange contracts to hedge these exposures.  Based on our foreign currency exchange rate exposure for intercompany advances of approximately $762,000 and $953,000 to our Canadian operations and Taiwan operations, respectively, at June 30, 2012, a 10% adverse change in the currency rates would reduce earnings before income taxes by approximately $171,500.

All transactions with our licensees are denominated in U.S. dollars so the licensee bears the currency exchange risk.  Accordingly, exchange rate fluctuations in international markets served by our licensees do not directly affect our results of operations.  However, exchange rate fluctuations in these markets may affect the ability of our licensees to conduct their business operations profitably.

ITEM 4. Controls and Procedures.

As required by Rules 13a-15(b) and 15d-15(b) under the Exchange Act, our management, including our Chief Executive Officer and Chief Financial Officer, evaluated as of June 30, 2012, the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures, as of June 30, 2012, were effective for the purpose of ensuring that information required to be disclosed by us in this report is recorded, processed, summarized and reported within the time periods specified by the rules and forms of the Exchange Act and is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer as appropriate to allow timely decisions regarding required disclosures.

There has been no change in internal control over financial reporting that occurred during the quarter ended June 30, 2012 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

- 20 -

PART II – OTHER INFORMATION

ITEM 1. Legal Proceedings.

On February 24, 2012, a medical/surgical dealer, which accounted for $1,900,000 and $2,148,000 of the Company's sales during the six months ended June 30, 2012 and 2011, respectively, filed a voluntary petition for protection under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Central District of California in Santa Ana, California. According to its bankruptcy petition, the dealer filed its petition as the most effective means of stabilizing its finances as it seeks to resolve a reimbursement guidelines dispute with Medicare. The dealer believes that Medicare is improperly withholding payments. While the reimbursement dispute does not involve products supplied by the Company, it has negatively affected the Company's sales to this dealer. The petition states that this dealer relies on Medicare payments for more than 90% of its revenue. On March 9, 2012, the Bankruptcy Court approved a "standstill" agreement between the dealer and Medicare, which agreement provides that Medicare would pay the dealer for certain claims it was withholding and that it would process and pay certain additional claims while the parties attempted to resolve the issues underlying the dispute. In a press release issued by the dealer, the dealer indicated that this agreement would provide it with the cash it requires to continue operations in the ordinary course of business and service its customers without interruption. As of the date of the bankruptcy filing, the Company had approximately $436,000 in accounts receivable that was owed by this dealer, and it has continued to fill this dealer's post-petition purchase orders.

On May 29, 2012, the Bankruptcy Court entered an order approving a Stipulated Motion of the dealer which directed the dealer to pay the Company for products that were shipped during the 20 day period immediately preceding the petition date. The accounts receivable owed by this dealer related to these shipments was approximately $195,000. The order directed the dealer to repay the Company in six equal installments of approximately $32,500, commencing on July 1, 2012. The first of these payments was received by the Company as ordered by the bankruptcy court.

The accounts receivable balance as of July 26, 2012 was approximately $690,000. While the Company believes that the amounts due from this dealer will be collected in full, it intends to monitor these proceedings as they progress in order to appropriately assess and enforce its rights in this matter.

The Company is from time to time engaged in routine litigation. The Company regularly reviews all pending litigation matters in which it is involved and establishes reserves deemed appropriate by management for these litigation matters.

ITEM 1A. Risk Factors.

Our business is subject to certain risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our common stock. For a discussion of these risks, please refer to the “Risk Factors” section of the 2011 Form 10-K. In connection with our preparation of this quarterly report, management has reviewed and considered these risk factors and has determined that there have been no material changes to our risk factors since the date of filing of the 2011 Form 10-K.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None

ITEM 3. Defaults Upon Senior Securities.

None

ITEM 4. Reserved.

ITEM 5. Other Information.

None

ITEM 6. Exhibits.

The Exhibit Index filed herewith is incorporated herein by reference.

- 21 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	RBC Life Sciences, Inc.
	Registrant
August 13, 2012	By:	/s/             Clinton H. Howard
Date	Its:	Chief Executive Officer
		(principal executive officer)
August 13, 2012	By:	/s/              Richard S. Jablonski
Date	Its:	Vice President - Finance and Chief Financial Officer
		(principal financial and accounting officer)

- 22 -

RBC LIFE SCIENCES, INC.

Exhibit Index

Exhibit Number	Description
31.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS	XBRL Instance Document **
101.SCH	XBRL Taxonomy Extension Schema Document **
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document **
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document **
101.LAB	XBRL Taxonomy Extension Label Linkbase Document **
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document **

** Filed electronically herewith

- 23 -